Progyny (PGNY) Stock Forecast & Price Target

$24.44

-0.38 (-1.53%)

(As of 09/18/2024 ET)

Progyny - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 11 Analyst Ratings

Based on 11 Wall Street analysts who have issued ratings for Progyny in the last 12 months, the stock has a consensus rating of "Hold." Out of the 11 analysts, 6 have given a hold rating, and 5 have given a buy rating for PGNY.

Consensus Price Target

$31.90
30.52% Upside

High Forecast	$43.00
Average Forecast	$31.90
Low Forecast	$24.00

According to the 11 analysts' twelve-month price targets for Progyny, the average price target is $31.90. The highest price target for PGNY is $43.00, while the lowest price target for PGNY is $24.00. The average price target represents a forecasted upside of 30.52% from the current price of $24.44.

Type	Current Forecast 9/19/23 to 9/18/24	1 Month Ago 8/20/23 to 8/19/24	3 Months Ago 6/21/23 to 6/20/24	1 Year Ago 9/19/22 to 9/19/23
Consensus Rating	Hold	Hold	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	9 Buy rating(s)	5 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$31.90	$31.90	$43.11	$49.43
Forecasted Upside	30.52% Upside	30.57% Upside	39.74% Upside	36.27% Upside

Here comes the May Shockwave (Ad)

Now that the Fed has spoken, it’s sure to create a May Shockwave! Now's your best chance to trade this historic event using the method that has seen Doubles, Even Triples within just a few days! You see, while most folks will be paying $500… $1,000… or even MORE to trade popular stocks like Apple, Nvidia, or Microsoft… I’ve discovered a new way to tap into what could be the cheapest options in a volatile market. You see, by entering on certain predetermined dates, we have been able to watch as these $0.25 Cent Trades doubled, even tripled in what feels like no time.

Click here to see the details so you don’t miss the next $0.25 Cent Trade!

PGNY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

PGNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Progyny Stock vs. The Competition

Type	Progyny	Medical Companies	S&P 500
Consensus Rating Score	2.45	2.77	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	30.52% Upside	1,009.48% Upside	7.94% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/20/2024	Cantor Fitzgerald 3 of 5 stars		Reiterated Rating	Overweight ➝ Overweight	$37.00 ➝ $37.00	+72.74%
8/19/2024	JPMorgan Chase & Co. 3 of 5 stars		Lower Target	Overweight ➝ Overweight	$41.00 ➝ $31.00	+47.34%
8/7/2024	Leerink Partnrs 0 of 5 stars	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/7/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Davides Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Market Outperform ➝ Market Outperform	$36.00 ➝ $31.00	+48.68%
8/7/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$37.00 ➝ $33.00	+67.26%
8/7/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold	$37.00 ➝ $24.00	-6.76%
Massive shakeup in defense contracting (Ad) There is a little-known energy technology stock that has made an incredible breakthrough… Which could become crucial to the operations of the US Military. And right now there are plans for this stock to undertake a major test project at a US Air Force based in Alaska. Now, this incredible breakthrough is still in its earliest stages… Which means you still have a chance to get in while its trading for under $10. You need to check out the full story right here.
8/7/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Larsen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/7/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$31.00 ➝ $25.00	-2.87%
5/13/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$48.00 ➝ $30.00	+9.73%
5/10/2024	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Schoenhaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Sector Weight
5/9/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$48.00 ➝ $50.00	+32.03%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:56 PM ET.

PGNY Forecast - Frequently Asked Questions

What is Progyny's forecast for 2024?: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Progyny is $31.90, with a high forecast of $43.00 and a low forecast of $24.00.
Should I buy or sell Progyny stock right now?: 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Progyny in the last twelve months. There are currently 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PGNY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PGNY, but not buy additional shares or sell existing shares.
Does Progyny's stock price have much upside?: According to analysts, Progyny's stock has a predicted upside of 30.10% based on their 12-month stock forecasts.
Has Progyny been downgraded by Wall Street analysts recently?: Over the previous 90 days, Progyny's stock had 4 downgrades by analysts.
What analysts cover Progyny?: Progyny has been rated by research analysts at BTIG Research, Canaccord Genuity Group, Canaccord Genuity Group, Cantor Fitzgerald, JMP Securities, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, and Truist Financial in the past 90 days.
Do Wall Street analysts like Progyny more than its competitors?: Analysts like Progyny less than other "medical" companies. The consensus rating for Progyny is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how PGNY compares to other companies.